RAS

1 clinical trials · Condition

Record	Firm	Date
The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer (NCT07257653)	Zhejiang University	2025-10-21

Every clearance here is in the API, with alerts when new ones post.